Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint

Published December 9, 2012

Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint

Filed under: drug treatment news 2011

9, 2012 — /PRNewswire/ — Sanofi (EURONEXT: SAN and NYSE: SNY) announced today new Phase II data showing that treatment with a novel, investigational, selective JAK2 inhibitor (SAR302503) reduced spleen size and improved constitutional … Starting …
Read more on Sacramento Bee

Omnicare's CEO Hosts Analyst Day Conference Call (Transcript)

Filed under: drug treatment news 2011

So if you look at this bar graph and you look at 2011, and look at the percent of spend in 2011 versus what projected in 2016. We see a substantial growth and specialty drugs over the next two years driven somewhat by inflation but also by utilization …
Read more on Seeking Alpha